TB Alliance regimen development for multidrug-resistant tuberculosis

International Journal of Tuberculosis and Lung Disease

Volumn 20, Issue 12, 2016, Pages S38-S41

  Murray, S ^a   Mendel, C ^a   Spigelman, M ^a  

^a Global Alliance for TB Drug Development (TB Alliance)   (United States)

Author keywords

Bedaquiline; Clinical trial; Moxifloxacin; Oxazolidinone; Pretomanid; Pyrazinamide; Tuberculosis

Indexed keywords

BEDAQUILINE; ETHAMBUTOL; ISONIAZID; LINEZOLID; MOXIFLOXACIN; PRETOMANID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT; 2-NITRO-6-(4-(TRIFLUOROMETHOXY)BENZYLOXY)-6,7-DIHYDRO-5H-IMIDAZO(2,1-B)(1,3)OXAZINE; NITROIMIDAZOLE DERIVATIVE; QUINOLINE DERIVATIVE; QUINOLONE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HEALTH CARE ORGANIZATION; HUMAN; MULTIDRUG RESISTANT TUBERCULOSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; PUBLIC HEALTH SERVICE; TREATMENT DURATION; TREATMENT OUTCOME; CLINICAL PROTOCOL; DOSE RESPONSE; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTITUBERCULAR AGENTS; CLINICAL PROTOCOLS; DIARYLQUINOLINES; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHAMBUTOL; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FLUOROQUINOLONES; HUMANS; ISONIAZID; LINEZOLID; NITROIMIDAZOLES; PYRAZINAMIDE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RIFAMPIN; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 85034714960     PISSN: 10273719     EISSN: 18157920     Source Type: Journal    
DOI: 10.5588/ijtld.16.0069     Document Type: Article

References (12)

1. Lin S Y, Desmond E P. Molecular diagnosis of tuberculosis and drug resistance. Clinics Laboratory Med 2014; 34: 297-314.
2. Mdluli K, Kaneko T, Upton A. The tuberculosis drug discovery and development pipeline and emerging drug targets. Cold Spring Harb Perspect Med 2015; 5. pii: a021154.
3. Pietersen E, Ignatius E, Streicher E M, et al. Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study. Lancet 2014; 383: 1230-1239.
4. Dawson R, Diacon A H, Everitt D, et al. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Lancet 2015; 385: 1738-1747.
5. Olaru I D, von Groote-Bidlingmaier F, Heyckendorf J, Yew W W, Lange C, Chang K C. Novel drugs against tuberculosis: a clinician's perspective. Eur Respir J 2015; 45: 1119-1131.
6. Dawson R, Diacon A. PA-824, moxifloxacin and pyrazinamide combination therapy for tuberculosis. Expert Opin Investig Drugs 2013; 22: 927-932.
7. World Health Organization. Global tuberculosis report, 2014. WHO/HTM/TB/2014.08. Geneva, Switzerland: WHO, 2014.
8. Leibert E, Danckers M, Rom W N. New drugs to treat multidrug-resistant tuberculosis: the case for bedaquiline. Ther Clin Risk Manag 2014; 10: 597-602.
9. Zhang Q, Liu Y, Tang S, Sha W, Xiao H. Clinical benefit of delamanid (OPC-67683) in the treatment of multidrug-resistant tuberculosis patients in China. Cell Biochem Biophys 2013; 67: 957-963.
10. Xavier A S, Lakshmanan M. Delamanid: a new armor in combating drug-resistant tuberculosis. J Pharmacol Pharmacother 2014; 5: 222-224.
11. Skripconoka V, Danilovits M, Pehme L, et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J 2013; 41: 1393-1400.
12. Ryan N J, Lo J H. Delamanid: first global approval. Drugs 2014; 74: 1041-1045.